{"url_path":"/sec/eltx/8-k/2026-06-24/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000050-index.html","accession_number":"0001601485-26-000050","cik":"0001601485","ticker":"ELTX","issuer_name":"Elicio Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000050-index.html","primary_entity_key":"0001601485","primary_entity_name":"Elicio Therapeutics, Inc."},"word_count":181,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn June 24, 2026, Elicio Therapeutics, Inc. (the “Company”) hosted a virtual key opinion leader event highlighting the path forward for ELI-002 7P in metastatic mutant KRAS-driven pancreatic ductal adenocarcinoma featuring key opinion leaders, Zev Wainberg, M.D., Professor of Medicine, UCLA, Co-Director of the UCLA GI Oncology Program, and Peter Hosein, M.D., Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of Miami. The presentation is furnished as Exhibit 99.1 to this report and is incorporated by reference herein.\n\nThe information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1."}